MALVERN, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) — Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced it will attend and present at the
Receive updates from Biotech Investments for free, starting right now.
We can deliver them by email, via your phone or you can read them from a personalised news page on follow.it.
This way you won't miss any new article from Biotech Investments. Unsubscribe at any time.
Site title: Biotech Investments – Independent Medical Rating Agency for Biotech and Pharmaceutical Assets. Purpose-built for Investors and Industry Partners.